Cargando…

Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia

OBJECTIVES: Lafutidine is a new H(2)-blocker in India claimed to be more potent and effective than existing H(2)-blockers. Proton pump inhibitors (PPIs), by virtue of their mechanism of action, have greater efficacy than H(2)-blockers in gastric acid suppression. However, clinical trials comparing H...

Descripción completa

Detalles Bibliográficos
Autores principales: Maity, Somnath, Choudhury, Supriyo, Hazra, Avijit, Das, Amal Kanti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175885/
https://www.ncbi.nlm.nih.gov/pubmed/25298578
http://dx.doi.org/10.4103/0253-7613.140580
_version_ 1782336550028181504
author Maity, Somnath
Choudhury, Supriyo
Hazra, Avijit
Das, Amal Kanti
author_facet Maity, Somnath
Choudhury, Supriyo
Hazra, Avijit
Das, Amal Kanti
author_sort Maity, Somnath
collection PubMed
description OBJECTIVES: Lafutidine is a new H(2)-blocker in India claimed to be more potent and effective than existing H(2)-blockers. Proton pump inhibitors (PPIs), by virtue of their mechanism of action, have greater efficacy than H(2)-blockers in gastric acid suppression. However, clinical trials comparing H(2)-blockers directly with PPIs are limited. We carried out a head-to-head comparison of the effectiveness of lafutidine versus the PPI pantoprazole in uninvestigated dyspepsia [CTRI/2013/12/004261]. MATERIALS AND METHODS: A prospective, open label, randomized, controlled trial was conducted in a tertiary care hospital. Ambulatory adult patients with dyspepsia, not yet subjected to endoscopy, were recruited if they had at least moderately severe symptoms, defined as a score of ≥ 4 on a 7-point Global Overall Symptom (GOS) Scale. Those with alarm features or significant comorbidity were excluded. Subjects received either once daily lafutidine 10 mg or pantoprazole 40 mg, orally, for 8 weeks. Reflux, dysmotility and pain scores were assessed by Modified Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease (mFSSGERD), and quality of life (QoL) by SF-8 scale. The latter had physical and mental components summarized by physical component summary score (PCS) and a mental component summary score (MCS). RESULTS: Of 122 patients enrolled, data of 57 on lafutidine and 60 on pantoprazole were analyzed. At 4 weeks, proportion of subjects responding (GOS score ≤ 2) in the two arms (lafutidine 45.61% vs. pantoprazole 48.33%, P = 0.854) or showing symptom resolution (GOS score ≤ 1) (lafutidine 12.28% vs. pantoprazole 5.00%; P = 0.197) were comparable. Similarly at 8 weeks, both responder (lafutidine 52.63% vs. pantoprazole 56.67%; P = 0.712) and symptom resolution proportions (lafutidine 33.33% vs. pantoprazole 30%; P = 0.843) were comparable. Total score on mFSSGERD scale, as well as all its three component scores, and PCS and MCS scores on QoL SF-8 scale showed improvement but no statistically significant difference between the two arms. Tolerability of both drugs was excellent. CONCLUSIONS: Lafutidine is well-tolerated and there is no clinically worthwhile difference between the two drugs in the empirical treatment of uninvestigated dyspepsia.
format Online
Article
Text
id pubmed-4175885
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-41758852014-10-08 Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia Maity, Somnath Choudhury, Supriyo Hazra, Avijit Das, Amal Kanti Indian J Pharmacol Research Article OBJECTIVES: Lafutidine is a new H(2)-blocker in India claimed to be more potent and effective than existing H(2)-blockers. Proton pump inhibitors (PPIs), by virtue of their mechanism of action, have greater efficacy than H(2)-blockers in gastric acid suppression. However, clinical trials comparing H(2)-blockers directly with PPIs are limited. We carried out a head-to-head comparison of the effectiveness of lafutidine versus the PPI pantoprazole in uninvestigated dyspepsia [CTRI/2013/12/004261]. MATERIALS AND METHODS: A prospective, open label, randomized, controlled trial was conducted in a tertiary care hospital. Ambulatory adult patients with dyspepsia, not yet subjected to endoscopy, were recruited if they had at least moderately severe symptoms, defined as a score of ≥ 4 on a 7-point Global Overall Symptom (GOS) Scale. Those with alarm features or significant comorbidity were excluded. Subjects received either once daily lafutidine 10 mg or pantoprazole 40 mg, orally, for 8 weeks. Reflux, dysmotility and pain scores were assessed by Modified Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease (mFSSGERD), and quality of life (QoL) by SF-8 scale. The latter had physical and mental components summarized by physical component summary score (PCS) and a mental component summary score (MCS). RESULTS: Of 122 patients enrolled, data of 57 on lafutidine and 60 on pantoprazole were analyzed. At 4 weeks, proportion of subjects responding (GOS score ≤ 2) in the two arms (lafutidine 45.61% vs. pantoprazole 48.33%, P = 0.854) or showing symptom resolution (GOS score ≤ 1) (lafutidine 12.28% vs. pantoprazole 5.00%; P = 0.197) were comparable. Similarly at 8 weeks, both responder (lafutidine 52.63% vs. pantoprazole 56.67%; P = 0.712) and symptom resolution proportions (lafutidine 33.33% vs. pantoprazole 30%; P = 0.843) were comparable. Total score on mFSSGERD scale, as well as all its three component scores, and PCS and MCS scores on QoL SF-8 scale showed improvement but no statistically significant difference between the two arms. Tolerability of both drugs was excellent. CONCLUSIONS: Lafutidine is well-tolerated and there is no clinically worthwhile difference between the two drugs in the empirical treatment of uninvestigated dyspepsia. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC4175885/ /pubmed/25298578 http://dx.doi.org/10.4103/0253-7613.140580 Text en Copyright: © Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Maity, Somnath
Choudhury, Supriyo
Hazra, Avijit
Das, Amal Kanti
Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia
title Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia
title_full Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia
title_fullStr Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia
title_full_unstemmed Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia
title_short Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia
title_sort randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175885/
https://www.ncbi.nlm.nih.gov/pubmed/25298578
http://dx.doi.org/10.4103/0253-7613.140580
work_keys_str_mv AT maitysomnath randomizedcontrolledtrialofeffectivenessoflafutidineversuspantoprazoleinuninvestigateddyspepsia
AT choudhurysupriyo randomizedcontrolledtrialofeffectivenessoflafutidineversuspantoprazoleinuninvestigateddyspepsia
AT hazraavijit randomizedcontrolledtrialofeffectivenessoflafutidineversuspantoprazoleinuninvestigateddyspepsia
AT dasamalkanti randomizedcontrolledtrialofeffectivenessoflafutidineversuspantoprazoleinuninvestigateddyspepsia